

Special Issue

Immunotherapeutics for Treating Infectious Diseases and Beyond

Message from the Guest Editors

Immunotherapy or immune-based therapy has a long history of success in the treatment of a wide range of human diseases, including cancer and infectious, metabolic, and autoimmune diseases, serving as a promising substitute to chemotherapeutics. This strategy involves the use of biological and/or synthetic agents to modulate host immune responses toward the cure. New technological advancements have been made to enhance the effects of therapeutic antibodies by employing several modifications, such as antibody engineering (Fc engineering, glycoengineering), as well as developing human, humanized, chimeric, and bispecific antibodies, etc. Despite this, in recent years, functional limitations related to immunotherapeutics, including inadequate pharmacokinetics and compromised non-specific interactions within the immune system, have been revealed and these deficits indicate the need to perform additional in-depth research and more significant efforts in this direction.

Guest Editors

Dr. Sneha Ratnapriya
Dr. Keerti Rawat
Dr. Yonatan Butbul Aviel

Deadline for manuscript submissions

closed (31 January 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/137288

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).